BIAF Plunges 77% as Cash Burn Overwhelms CyPath Traction

What happened

bioAffinity's stock has collapsed 77% in three months as the market repriced persistent cash burn and dilution risk, despite continued CyPath Lung adoption. Q1 2026 CyPath revenue rose 114% year-over-year to $361,000, but total revenue fell 36% to $1.35 million and operating cash burn reached $3.23 million. The June 2026 equity offering added only $2.6 million net, barely extending the runway while increasing shares outstanding by 40%. The narrative has shifted from commercial momentum to funding survival, with the company's going-concern warning still in place. Until the next quarterly filing shows CyPath can lift consolidated revenue and reduce burn, the stock remains a high-risk hold.

Implication

An attractive entry may emerge near $0.70 if Q2 2026 shows CyPath revenue above $500K and operating burn below $2.5M, but another dilutive raise is likely before then; the bull case depends on institutional orders and faster scale.

Thesis delta

The thesis has shifted from early-stage commercialization optimism to a funding-risk-dominated scenario. While CyPath adoption is real, the speed of cash consumption and reliance on dilutive capital have overwhelmed near-term upside potential. The window for positive catalysts has narrowed significantly—even strong CyPath growth may not lift the stock unless it materially changes the cash trajectory.